Printer Friendly

RAYTHEON UNIT WINS PHARMACEUTICAL CONTRACT FROM HOFFMANN-LA ROCHE

RAYTHEON UNIT WINS PHARMACEUTICAL CONTRACT FROM HOFFMANN-LA ROCHE
 LEXINGTON, Mass., May 4 /PRNewswire/ -- Raytheon Company (NYSE: RTN) announced today that its United Engineers & Constructors (UE&C) subsidiary has been selected by Roche Carolina Inc., a subsidiary of Hoffmann-La Roche Inc., to provide design and engineering services for a new pharmaceutical process development and manufacturing complex in Florence, S.C.
 The complex, which has an estimated capital cost of $500 million, will include a process research and development facility, a bulk pharmaceutical manufacturing plant, and complete site infrastructure.
 Under a 10-year partnering relationship with Roche Carolina, UE&C will provide architectural master planning, engineering, equipment procurement, and validation services for the multi-phase development of the complex.
 Raytheon, headquartered in Lexington, Mass., is a $9.3 billion diversified, international, technology company with sales in four business segments: Electronics, Aircraft Products, Energy and Environmental, and Major Appliances.
 -0- 5/4/92
 /CONTACT: Ed Powers of Raytheon, 617-860-2415, or Christine Robertson of United Engineers & Constructors, 215-422-3419/
 (RTN) CO: United Engineers & Constructors ST: Massachusetts, Pennsylvania IN: SU: CON


SH -- NE027 -- 6190 05/04/92 16:12 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 4, 1992
Words:182
Previous Article:U.S. EPA, STATE OF CALIFORNIA PROPOSE PERMIT FOR DOW INCINERATOR
Next Article:MOOG REPORTS $2 MILLION PROFIT


Related Articles
HOFFMANN-LA ROCHE ACQUISITION OF PCR TECHNOLOGY COMPLETED; ROCHE AND PERKIN-ELMER FORM STRATEGIC ALLIANCE
ALPHA 1 BIOMEDICALS COMPLETES ACQUISITION OF U.S. RIGHTS TO THYMOSIN ALPHA 1 FROM HOFFMANN-LA ROCHE
RAYTHEON'S SECOND QUARTER EARNINGS INCREASE 9.0 PERCENT
RAYTHEON'S SECOND QUARTER EARNINGS INCREASE 9.0 PERCENT
RAYTHEON 1992 HIGHLIGHTS
GENETICS INSTITUTE COMMENCES DEVELOPMENT OF NEW BLOOD CELL GROWTH AND STIMULATORY FACTOR
GENSIA APPOINTS HERBERT CONRAD TO BOARD OF DIRECTORS
DURA PHARMACEUTICALS APPOINTS HERBERT CONRAD TO BOARD OF DIRECTORS
MILLENNIUM PUBLICATION DESCRIBES CLONING OF THE MOUSE tub GENE AND ITS HUMAN HOMOLOGUE
Weston Medical Grants First Global License to Hoffmann-La Roche

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters